LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations

To report preliminary data on baseline serum calcitonin concentrations and associated clinical characteristics in a global population with type 2 diabetes before liraglutide or placebo randomization.

[1]  B. Zinman,et al.  Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. , 2013, American heart journal.

[2]  P. Rosário,et al.  Influence of chronic autoimmune thyroiditis and papillary thyroid cancer on serum calcitonin levels. , 2013, Thyroid : official journal of the American Thyroid Association.

[3]  W. Al-Delaimy,et al.  Should food intake and circadian rhythm be considered when measuring serum calcitonin level? , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[4]  M. Wolf,et al.  Association of serum calcitonin with coronary artery disease in individuals with and without chronic kidney disease , 2012, International Urology and Nephrology.

[5]  Afsar Barlas,et al.  GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. , 2012, Endocrinology.

[6]  G. Daniels.  Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada. , 2011, Thyroid : official journal of the American Thyroid Association.

[7]  H. Gharib,et al.  Thyroid nodule guidelines: agreement, disagreement and need for future research , 2011, Nature Reviews Endocrinology.

[8]  L. Hegedüs,et al.  GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. , 2011, The Journal of clinical endocrinology and metabolism.

[9]  L. Giovanella,et al.  Spurious hypercalcitoninemia and heterophilic antibodies in patients with thyroid nodules , 2011, Head & neck.

[10]  H. Gharib,et al.  AACE / AME / ETA Guidelines AMERICAN ASSOCIATION Of ClINICAl ENDOCRINOlOgISTS , ASSOCIAzIONE MEDICI ENDOCRINOlOgI , AND EuROPEAN ThyROID ASSOCIATION MEDICAl guIDElINES fOR ClINICAl PRACTICE fOR ThE DIAgNOSIS AND MANAgEMENT Of ThyROID NODulES , 2010 .

[11]  K. Almholt,et al.  Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. , 2010, Endocrinology.

[12]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[13]  L. Hegedüs,et al.  Benefit of measuring basal serum calcitonin to detect medullary thyroid carcinoma in a Danish population with a high prevalence of thyroid nodules , 2009, Head & neck.

[14]  J. Rosenstock,et al.  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) , 2009, The Lancet.

[15]  G. Böhmig,et al.  Prevalence of hypercalcitoninemia in patients on maintenance dialysis referred to kidney transplantation. , 2009, Clinical nephrology.

[16]  B. Bode,et al.  Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial , 2009, The Lancet.

[17]  P. Caron,et al.  Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking. , 2007, European journal of endocrinology.

[18]  M. Maranghi,et al.  Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. , 2007, The Journal of clinical endocrinology and metabolism.

[19]  M. Erdoğan,et al.  Long-term effects of elevated gastrin levels on calcitonin secretion , 2006, Journal of endocrinological investigation.

[20]  D. Vallone,et al.  Smoking, obesity, and their co-occurrence in the United States: cross sectional analysis , 2006, BMJ : British Medical Journal.

[21]  L. Hegedüs,et al.  The Thyroid Nodule , 2004 .

[22]  P. Niccoli,et al.  Pentagastrin testing in patients with renal insufficiency: normal responsivity of mature calcitonin. , 1998, Thyroid : official journal of the American Thyroid Association.

[23]  A. Winship.  Interest. , 1893 .

[24]  Sebastiano Filetti,et al.  Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls , 2009, Nature Clinical Practice Endocrinology &Metabolism.

[25]  L. Hegedüs,et al.  Clinical practice. The thyroid nodule. , 2004, The New England journal of medicine.

[26]  D. Chappard,et al.  Sex-related C cell hyperplasia in the normal human thyroid: a quantitative autopsy study. , 1997, The Journal of clinical endocrinology and metabolism.

[27]  E. Baudin,et al.  Abnormal calcitonin basal levels and pentagastrin response in patients with chronic renal failure on maintenance hemodialysis. , 1995, European journal of endocrinology.